Please assess the completion status of the following clinical trial:

Trial Title: CoolLoop Paroxysmal Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 - 70 years~* symptomatic paroxysmal Atrial fibrillation (AF)~* a minimum of three episodes of paroxysmal AF~* at least one episode of paroxysmal AF within the last 6 months documented by ECG~* signed and dated informed consent documented by the patient~* female subjects of childbearing potential can be included, if they: agree to use, and be able to comply with, effective contraception without interruption, from study enrollment, throughout hospitalization and until 12 weeks after catheter ablation~Exclusion Criteria:~* left atrial diameter \> 50 mm in the short axis as assessed by transthoracic echocardiography~* advanced structural heart disease including~  * moderate-to-severe valvular stenosis or regurgitation,~ * previous valve replacement or valve repair,~ * congenital heart disease,~ * left ventricular ejection fraction \< 45% during sinus rhythm,~ * congestive heart failure New York Heart Association (NYHA) III or IV,~ * coronary artery bypass graft surgery within the last 3 months~* chronic obstructive pulmonary disease treated with beta-sympathomimetic drugs~* severe respiratory insufficiency~* known bleeding diathesis~* intolerance of Heparin and/or intolerance of oral anticoagulation~* previous AF ablation~* permanent pacemaker~* left atrial thrombus~* intramural or intracardiac thrombus or tumor, or other conditions that may result in difficulties advancing the CoolLoop® cryoablation catheter into the left atrium~* access to the vascular system via the right or left femoral vein is not possible~* transseptal puncture cannot be achieved due to a previous operation or intervention at the interatrial septum (e.g. closure of a patent foramen ovale or atrial septal defect)~* contraindication for transesophageal echocardiography or fluoroscopy~* impaired renal function (glomerular filtration rate \<30 ml/min.)~* history or increased risk of intracranial hemorrhage~* history of cerebral ischemic stroke or transient ischemic cerebral attacks within the last 180 days prior to enrolment~* severe comorbidity~* hyperthyreosis~* any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he / she were to participate in the study or confound the ability to interpret data from the study~* any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the Informed Consent Form~* pregnant or lactating females~* other severe conditions, which makes the patient unsuitable to participate in the study, as judged by the Investigator~* live-expectancy \< 1 year~* the patient is active in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cryoablation (Type: EXPERIMENTAL): Cryoablation with the CoolLoop® catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues